Nexus Investment Management ULC Grows Position in Pfizer Inc. (NYSE:PFE)

Nexus Investment Management ULC boosted its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 5.9% during the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 866,837 shares of the biopharmaceutical company's stock after purchasing an additional 48,550 shares during the quarter. Pfizer comprises 3.3% of Nexus Investment Management ULC's portfolio, making the stock its 16th largest position. Nexus Investment Management ULC's holdings in Pfizer were worth $21,966,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Exeter Financial LLC raised its holdings in Pfizer by 88.5% in the 1st quarter. Exeter Financial LLC now owns 28,195 shares of the biopharmaceutical company's stock worth $714,000 after acquiring an additional 13,239 shares during the last quarter. Quent Capital LLC grew its holdings in shares of Pfizer by 15.1% in the first quarter. Quent Capital LLC now owns 12,878 shares of the biopharmaceutical company's stock worth $326,000 after acquiring an additional 1,694 shares during the period. Legacy Private Trust Co. boosted its position in Pfizer by 4.4% in the first quarter. Legacy Private Trust Co. now owns 14,366 shares of the biopharmaceutical company's stock worth $364,000 after purchasing an additional 600 shares during the last quarter. Central Pacific Bank Trust Division grew its stake in shares of Pfizer by 19.4% during the 1st quarter. Central Pacific Bank Trust Division now owns 21,634 shares of the biopharmaceutical company's stock valued at $548,000 after purchasing an additional 3,516 shares during the period. Finally, Versant Capital Management Inc lifted its stake in shares of Pfizer by 186.0% in the 1st quarter. Versant Capital Management Inc now owns 19,446 shares of the biopharmaceutical company's stock worth $493,000 after purchasing an additional 12,647 shares during the period. Institutional investors own 68.36% of the company's stock.

Wall Street Analysts Forecast Growth

PFE has been the topic of several analyst reports. Citigroup reiterated a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a report on Monday, March 10th. Cantor Fitzgerald initiated coverage on Pfizer in a report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price target on the stock. The Goldman Sachs Group reaffirmed a "neutral" rating and issued a $25.00 price objective (down previously from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Finally, Guggenheim reissued a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have given a buy rating and three have assigned a strong buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $29.17.

Pfizer Trading Up 0.0%

Shares of NYSE PFE traded up $0.01 during mid-day trading on Friday, reaching $23.46. The company had a trading volume of 56,576,195 shares, compared to its average volume of 41,238,982. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The stock has a market cap of $133.38 billion, a price-to-earnings ratio of 16.64, a price-to-earnings-growth ratio of 0.64 and a beta of 0.58. The business's 50-day moving average is $23.12 and its 200-day moving average is $25.07. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping the consensus estimate of $0.67 by $0.25. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company had revenue of $13.72 billion for the quarter, compared to the consensus estimate of $14.43 billion. During the same period last year, the business posted $0.82 EPS. Pfizer's quarterly revenue was down 7.8% on a year-over-year basis. Equities analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Friday, May 9th will be issued a $0.43 dividend. The ex-dividend date is Friday, May 9th. This represents a $1.72 annualized dividend and a dividend yield of 7.33%. Pfizer's dividend payout ratio is currently 124.64%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.